Ocugen Stock News

Atreca (BCEL) +20%. Alignment Healthcare (ALHC) +16%. DBV Technologies DBVT -22%. Ocugen OCGN -20%.

The FDA has declined to issue an Emergency Use Authorization (EUA) for Covaxin for active immunization to prevent COVID-19 in individuals 2 to 18 years of age. Ocugen Inc (NASDAQ: Full story available on Benzinga.com

Ocugen OCGN -27% after request for pediatric use of COVID-19 vaccine rejected by FDA.Smith & Wesson Brands SWBI -21% on Q3 earnings release.DBV Technologies DBVT -21% on FY…

Ocugen entered into a deal with vaccine maker Bharat Biotech in late 2020, under which it would develop, supply, and commercialize Covaxin for the US market.

Bharat Biotech''s US partner Ocugen said it intends to continue working with the US FDA to evaluate the process for getting an EUA for pediatric use of Covaxin

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck''s Keytruda Evaluated In Combination With Microbiome Therapeutic In Biliary Tract Cancer South Korea''s Genome and Company, a developer of microbiome anti-cancer drug, said it has entered into a first clinical trial collaboration and supply agreement with Merck & Company, Inc. (NASDAQ: MRK ). Under the agreement, the Korean company will conduct a Phase 2 clinical trial to evaluate the safety and efficacy of its immuno-oncology microbiome therapeutic, GEN-001, in combination with Merck''s Keytruda in patients with biliary tract cancer. Genome and Company will be the sponsor of the clinical trial and Merck will supply Keytruda. vTv Announces Resignation Of CEO, Appoints Board Member Rich Nelson As Acting CEO vTv Therapeutics, Inc. (VTVT) announced the appointment of Rich Nelson as acting chief executive officer. Nelson joined the vTv board in 2020 and … Full story available on Benzinga.

Ocugen (OCGN) is trading ~29% lower in the pre-market Friday after announcing that the U.S

MALVERN, Pa., March 04, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cur

The U.S. FDA refused to grant Emergency Use Authorization for COVID-19 vaccine Covaxin in immunizing kids.

Shares of OCGN stock are in the red after the company's Covaxin Covid-19 vaccine was declined EUA by the FDA. Here's what you should know.

Ocugen (OCGN) stock is falling hard on Friday after the FDA rejected its Emergency Use Authorization request for Covaxin. The post Ocugen Latest News: What OCGN Stock Investors Need to Know About the

Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 22.8% at $2.54 after the company announced the FDA declined to issue an EUA for COVAXIN for active immunization to prevent COVID-19 caused by SARS

Sector ETF report for XBI

Momentum from the company's fourth-quarter update on Friday is carrying over into this week.

Momentum from the company''s fourth-quarter update on Friday is carrying over into this week.